Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial

Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial

10.1016/j.ygyno.2017.02.039

Saved in:
Bibliographic Details
Main Authors: Wysham, Weiya Z, Schaffer, Elisabeth M, Coles, Theresa, Roque, Dario R, Wheeler, Stephanie B, Kim, Kenneth H
Other Authors: DUKE-NUS MEDICAL SCHOOL
Format: Article
Published: Elsevier BV 2023
Subjects:
Cost-effectiveness
Bevacizumab
Aurelia
Online Access:https://scholarbank.nus.edu.sg/handle/10635/239625
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Description
Summary:10.1016/j.ygyno.2017.02.039

Similar Items